Cheap version of HIV-prevention shot raising hope in low-income countries
Reported byCBC Health ↗·Sourced by Goodlede
The FDA has approved a generic version of lenacapavir, a twice-yearly HIV-prevention injection, expected to cost $40 USD annually per person in 120 low- and middle-income countries. The drug nearly eliminated new infections in two major studies and offers far more convenience than daily preventive pills.
The generic version cannot be sold in the U.S. due to patent protection of the brand-name version, which costs $28,218 annually.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at CBC Health
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Human Feats
Karl Bushby completes 28-year, 31,000-mile walk around the world and returns to his mother's house
Associated Press · Verified
Environment
Electric trucks hit 50% of China's heavy truck sales, diesel demand falls
Electrek · Verified
David vs Goliath
TD tried to make grieving mom pay $38K in student debt after daughter died of cancer
CBC Canada · Verified